Characterization of the metabolism and disposition of a drug candidate in preclinical species is a routine part of drug discovery and development.
| ATV dose solution preparation for monkey
Monkeys were dosed with ATV in a suspension formulation.
Suspension formulations were prepared for the study on the morning of dosing. Briefly, ATV tablets totaling 1 gram active were placed in a mortar and pestle and crushed into a fine powder. Suspension vehicle (0.5% methylcellulose E4M/0.02% Docusate Sodium) was slowly added to the powder to form a suspension at the desired concentration. The formulation was triturated until a homogenous suspension was formed.
| ATV dosing and sample collection in intact dogs and monkeys

| Dogs
Beagle dogs (n = 3, males) were orally dosed ATV tablets at 40 mg/ kg 1 hour after a morning meal in order to prevent gallbladder emptying after compound dosing and to allow for bile collection at an optimal time. Plasma samples were collected at 0.5, 1, 2, 4, 6, and 24 hours postdose via cephalic vein or indwelling cephalic catheter.
At the 6-and 24-hours postdose time points, dogs were sedated with propofol at 6 mg/kg through an indwelling cephalic catheter.
The dogs were then positioned in a dorsal-recumbency with head elevated. Heart rate, rhythm, and arterial oxygen saturation were monitored throughout the procedure. After shaving and aseptically preparing the abdominal skin immediately caudal to the xiphoid process, an ultrasound exam of the gallbladder and cranial abdomen was done using a Mylab30cv ultrasound system with 9-3 MHz micro-convex transducer (Esoate, Indianapolis, IN). A 21-gauge, 1.5-inch needle, attached to a 5-mL syringe, was inserted percutaneously through the abdominal wall into the gallbladder lumen.
Effort was made to completely empty the gallbladder by aspiration (typically, 2-5 mL bile was obtained). The needle and syringe were withdrawn and the bile samples were immediately saved on dry ice for later analysis. Dogs were allowed to recover in their home cages.
Both plasma and bile samples were stored at −20°C until analysis.
| Monkeys
Cynomolgus macaques (n = 3, males) were orally dosed 30 mg/kg ATV suspension by gavage. Plasma and bile samples were collected.
For bile collection monkeys were sedated with ketamine (8 mg/kg) and dexmedetomidine (0.05 mg/kg) intramuscularly. At the conclusion of the procedure, sedation was reversed with atipamezole (0.15 mg/kg) intramuscularly. All other procedures were the same as for the dog.
| ATV dosing and sample collection in BDC dogs and monkeys
Bile duct-cannulated beagle dogs (n = 3, males) were orally dosed ATV tablets at 40 mg/kg. BDC cynomolgus macaques (n = 4, males) were orally dosed 30 mg/kg ATV suspension by gavage. Plasma samples were collected from dogs and monkeys at 0.5, 1, 2, 4, 6, and 24 hours postdose. Bile samples were collected at 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, and 8-24 hours intervals. Both plasma and bile samples were stored at −20°C until analysis.
| Quantification of ATV and its metabolites by LC-MS/MS analysis
Quantification of ATV and its metabolites in dog and monkey plasma and bile was performed using LC-MS/MS-based analysis. Standard curves and quality control (QC) samples defining the dynamic range of the bioanalytical method were prepared in commercially available control plasma and processed in the same fashion as the test samples. When dilutions were required, an aliquot of the sample was diluted into control plasma. Aliquots (50 µL) of plasma or bile diluted into plasma from in vivo study and standard/QC samples were treated with acetonitrile (150 µL) containing internal standard SIL-ATV (0.2 µmol/L), followed by vortex mixing for 2 minutes.
The supernatant was then separated from the precipitated proteins after a 10-minute centrifugation at 3500 rpm (2109× g) at 10°C and transferred to an autosampler 96-well plate. An aliquot (10 µL) was injected onto the ultrahigh performance liquid chromatography (UHPLC) column for LC-MS/MS-based analysis. Samples from individual animals were not pooled prior to quantitative analysis.
The UHPLC system Nexera (Shimadzu, Japan) consisted of two pumps (LC30AD), a column heater (CTO-30A), and an autosampler (SIL-30AC) equipped with a cooling compartment that maintained samples at 15°C during analysis. The analytical column used was a BEH C18 2.1 mm × 50 mm, 1.7 µm (Waters Corporation, Milford, MA) at 50°C. The mobile phase, which consisted of 0.1% formic acid in water (A) and acetonitrile (B), was delivered at a flow rate of 0.6 mL/min. The initial conditions were 100% aqueous followed by 1-minute gradient to 100% acetonitrile then hold for 0.4 minutes and back to initial conditions. The retention times of each compound were as follows: ATV and SIL-ATV at 1.28 minutes, 2-OH ATV at 
| Plasma pharmacokinetic analysis
The (Table 1) . Table 2 
| Metabolite profile of ATV in bile obtained by cholecystocentesis and bile duct-cannulation in dogs
Representative dog bile UV chromatograms from 6 and 24 hours UCC samples and 0-24 hours pooled BDC samples are shown in 
| D ISCUSS I ON
ATV was chosen as a probe compound to evaluate the use of UCC for metabolite profiling due to its great extent of metabolism and biliary excretion. Biliary excretion is reported to be a major route of elimination for ATV and its metabolites in dog, accounting for 33% of the oral dose, with peak biliary excretion at 4-8 hours. 17 In the current study both intact (UCC) and BDC dogs and monkeys were dosed orally with ATV, and the plasma pharmacokinetic parameters and the biliary metabolite profiles were evaluated. Previously published ATV studies in the dog guided the study design of both dog and monkey studies. 17, 18 There are no previously published reports on the ATV metabolite profiles in monkey. Time points for bile sampling via UCC were set based on the peak recovery from BDC dogs in a previous report. 17 Authentic standards of ATV and some of the oxidative metabolites were used for quantification in plasma and bile of the dogs and monkeys. In the dog, both plasma and bile concentrations were broadly similar in both the UCC and BDC samples. Higher plasma concentrations in the UCC dogs may be due to enterohepatic recirculation, which cannot occur in BDC dogs. At the 6 hours collection, concentrations of ATV and metabolites trended lower in the UCC bile; this may reflect some dilution due to residual bile in the gallbladder since the gallbladder was not deliberately emptied prior to dosing. Higher trends in ATV and metabolite bile concentrations at the 24 hours UCC collection may be due to enterohepatic recirculation of ATV and are consistent with the plasma concentrations.
The metabolite concentrations trended lower in plasma and higher in bile of the UCC monkeys compared to the BDC monkeys. The reason for this difference is unknown but may indicate differences in enzyme or transporter levels between the intact (UCC) and BDC animals. Such differences between intact and BDC animals have been noted in the literature and may be a result of inflammation in the BDC monkeys. [1] [2] [3] [4] [5] Another potential source of minor differences between the UCC and BDC profiles is the sedative administered at 4-6 hours and again at 24 hours prior to the cholecystocentesis. It
TA B L E 3
Comparison of plasma pharmacokinetic parameters ± standard deviation after a 30 mg/kg oral dose of ATV in BDC (n = 4) and UCC (n = 3) monkeys TA B L E 4 Concentration ± standard deviation of ATV and the oxidative metabolites, 2-OH ATV, 4-OH ATV, 2-OH ATV-L, and 4-OH ATV-L, in bile from BDC and UCC monkeys dosed 30 mg/kg ATV orally Abbreviations: ATV, atorvastatin; BDC, bile duct-cannulated; UCC, ultrasound-guided cholecystocentesis. a n = 2 due to blocked/displaced cannulas. b n = 1; other samples below the lower limit of quantitation.
is not known whether the sedative could have a transient effect on metabolic enzymes or transporters which could result in differences in the profiles from 4-6 hours to 24 hours postdosing. This would not impact the absorption of ATV or the early phase of the plasma or bile profiles.
In general the dog and monkey metabolite profiles in bile were similar. In both monkey and dog, the primary metabolic pathway observed for ATV was oxidative metabolism. In addition, glucuronide conjugates of ATV and metabolites with combined glucuronidation and oxidation were also detected. Based on the UV chromatograms, 2-OH ATV and 4-OH ATV were the major oxidative metabolites in both dog and monkey bile. There were also, however, some differences between the species. There were three isomer metabolites with m/z 694, assigned as the mono-oxidation and S-cysteine conjugation metabolites that were observed in monkey bile but were either not detected or were present only in trace amounts in dog In conclusion, the current results demonstrate the utility of UCC for collecting bile samples from dogs and monkeys for metabolite profiling of compounds that undergo biliary elimination.
Bile samples obtained through UCC may be considered similar to pooled bile samples from BDC animals in that they represent an accumulation of metabolites between dosing and sample time.
Thus, UCC is a viable alternative methodology to help investigate drug candidate metabolism and disposition. This technique may provide sufficient metabolism data to obviate the need for investigations using surgically prepared dogs or monkeys, particularly in drug discovery. Alternatively, it could be used as a complement to a BDC study to provide a more complete picture of the metabolic pathways and excretion in intact animals. Additionally UCC avoids possible sample contamination that can occur with other alternative sampling methods and may be translational to clinical ADME studies. 
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